Axsome Therapeutics
AXSM
Axsome Therapeutics (AXSM) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.99
- EPS estimate
- −$0.89
- EPS surprise
- −10.97%
- Revenue surprise
- −2.15%
- Revenue
- $216.4M
- Revenue estimate
- $221.1M
- Reported
- Aug 10, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.89 | −$0.99 | −10.97% | $216.4M | SEC |
| Q1 2026 | May 4, 2026 | −$0.81 | −$1.26 | −54.70% | $189.4M | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.69 | −$0.56 | +19.13% | $194.7M | SEC |
| Q3 2025 | Nov 3, 2025 | −$0.86 | −$0.94 | −9.15% | $171.0M | SEC |
| Q2 2025 | Aug 4, 2025 | −$1.06 | −$0.97 | +8.07% | $150.0M | SEC |
| Q1 2025 | May 5, 2025 | −$1.35 | −$1.22 | +9.71% | $121.5M | SEC |
| Q4 2024 | Feb 18, 2025 | −$1.00 | −$1.54 | −53.85% | $118.8M | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.38 | −$1.34 | +3.14% | $103.7M | SEC |
| Q2 2024 | Aug 5, 2024 | −$1.31 | −$1.67 | −27.76% | $87.2M | SEC |
| Q1 2024 | May 6, 2024 | −$1.20 | −$1.44 | −19.55% | $75.0M | SEC |
| Q4 2023 | Feb 20, 2024 | −$1.17 | −$2.08 | −77.57% | $71.5M | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.20 | −$1.32 | −9.70% | $57.8M | SEC |
| Q2 2023 | Aug 7, 2023 | −$1.21 | −$1.54 | −26.91% | $46.7M | SEC |
| Q1 2023 | May 8, 2023 | −$1.30 | −$0.26 | +80.06% | $94.6M | SEC |
| Q4 2022 | Feb 27, 2023 | −$1.13 | −$1.41 | −25.23% | $24.4M | SEC |
| Q3 2022 | Nov 7, 2022 | −$1.05 | −$1.07 | −1.90% | $16.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$1.01 | −$1.06 | −5.36% | $8.8M | SEC |
| Q1 2022 | May 2, 2022 | −$1.00 | −$1.03 | −2.72% | $0.00 | SEC |
| Q4 2021 | Mar 1, 2022 | −$1.02 | −$0.90 | +11.89% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.95 | −$0.93 | +2.50% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Axsome Therapeutics (AXSM) last report earnings?
Axsome Therapeutics last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did AXSM beat earnings estimates?
No. Axsome Therapeutics reported EPS of −$0.99 for Q2 2026 against a −$0.89 estimate — a 10.97% miss.
How much revenue did AXSM report last quarter?
Axsome Therapeutics reported $216.4M in revenue for Q2 2026, against a consensus estimate of $221.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.